| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司主要产品为甾体药物生产所需的起始物料、中间体和原料药，为甾体药物起始物料领域的重要企业，依托起始物料产品的优势，形成了皮质激素、性激素、孕激素系列中间体相对完整的产业链，是国内甾体药物中间体的重要研发和生产基地。 目前共同药业拥有3个生产基地，不仅拥有符合GMP证书体系的生产设备，且均在稳定的EHS系统上进行生产活动的运作，稳定且安全的生产为客户提供了稳定的产品产能输出。 位于武汉和杭州的2个研究院，专注于分子生物学、酶工程、发酵工程、化学合成的研发创新，在推动公司新产品、新工艺研发的同时，继续拓展与国内外高校和科研院所的项目合作，为公司打造更稳固的核心竞争力，为公司未来发展储备技术和人才力量。 | ||||||||||||||||||||||||
| Main Business | 从事甾体药物原料的研发、生产和销售 | ||||||||||||||||||||||||
| Legal Representative | 系祖斌 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 陈文静 | ||||||||||||||||||||||||
| Solicitors | 北京市中伦律师事务所 | ||||||||||||||||||||||||
| Auditors | 大信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0710-3523126 | ||||||||||||||||||||||||
| Fax No | 0710-3423126 | ||||||||||||||||||||||||
| Website | www.gotopharm.com | ||||||||||||||||||||||||
| board@gotopharm.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 09/04/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.200 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.016 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 7.428 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 1.343B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |